Daiichi Sankyo and NGM Biopharmaceuticals have entered into a research collaboration and licence agreement to discover and develop therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

Under the agreement, NGM will apply its integrated discovery technology and in vivo screening platform to identify and validate physiologically-relevant metabolic targets that modulate beta-cell growth and function. Daiichi Sankyo will assume responsibility for preclinical studies, clinical development, manufacturing and commercialisation across the world.

As part of the collaboration, Daiichi Sankyo and NGM will jointly conduct research on selected targets with the goal of identifying and optimising drug candidates for further development.

NGM will receive an upfront payment and committed research funding for the duration of the collaboration, and is also eligible to receive payments upon the achievement of research, development, regulatory and commercial milestones, as well as royalties on product sales.

Daiichi Sankyo will receive an exclusive worldwide licence to develop and commercialise compounds resulting from the collaboration, as per the deal.

NGM chief scientific officer, president and founder Jin-Long Chen said the company has established a translational research platform based on human biology that is capable of discovering novel drug targets, and they look forward to applying its technology to the emerging area of beta-cell regeneration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Daiichi Sankyo R&D Unit global head Kazunori Hirokawa said the collaboration will result in an innovative pharmaceutical product that meets an unmet medical need in the cardiovascular metabolic area.

NGM is a privately-held drug discovery company focused on the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases.

Daiichi Sankyo Group will create and supply innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.